Page 97 - Human Use News Today

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta

AstraZeneca and MSD's Lynparza approved in the EU for prostate cancer

LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L), on Wednesday, announced that Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the European Union

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European...

/PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of...

ADC Therapeutics SA and Swedish Orphan Biovitrum AB announced the European Commission has granted conditional marketing authorization for the use of ZYNLONTA® for the treatment of relapsed or... | December 21, 2022

Approval triggers $50 million milestone payment to ADC Therapeutics ... | December 21, 2022

EU patients with an advanced prostate cancer will benefit from a newly approved Lynparza-based treatment combination for the first time.

LONDON (dpa-AFX) - British drug major AstraZeneca Plc.'s (AZN.L, AZN) Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adult patients with unresectable

The process is now so burdensome that “it’s almost unfeasible to run very large trials in a sensible way,” Louise Bowman says.